Inflammatory pathways underlying atrial fibrillation

Trends in Molecular Medicine

Volumn 17, Issue 10, 2011, Pages 556-563

  Friedrichs, Kai ^a   Klinke, Anna ^a   Baldus, Stephan ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLOROTYROSINE; CONNEXIN 40; CONNEXIN 43; DIPEPTIDYL CARBOXYPEPTIDASE; GAP JUNCTION PROTEIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; PHOSPHOLIPASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD FLOW VELOCITY; CALCIUM CHANNELOPATHY; CARDIOVERSION; CELL INFILTRATION; CORONARY ARTERY BYPASS GRAFT; CYTOKINE RELEASE; DYSPNEA; ELECTROCARDIOGRAM; FIBROSIS; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART DEPOLARIZATION; HEART MUSCLE FIBROSIS; HEART PALPITATION; HYPERTENSION; INFLAMMATION; LEUKOCYTE ACTIVATION; NEUTROPHIL; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICARDITIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; THORAX PAIN; THROMBOEMBOLISM;

ANIMALS; ATRIAL FIBRILLATION; CONNEXINS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LEUKOCYTES;

EID: 80053569137     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.05.007     Document Type: Review

References (85)

1. Kannel W.B., et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. 1982, 306:1018-1022.
2. Tsang T.S., et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J. Am. Coll. Cardiol. 2003, 42:93-100.
3. Wang T.J., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J. Am. Med. Assoc. 2003, 290:1049-1056.
4. Haïssaguerre M., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998, 339:659-666.
5. Morady F. Treatment of paroxysmal atrial fibrillation by pulmonary vein isolation. Circ. J. 2003, 67:567-571.
6. Verma A., et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur. Heart J. 2010, 31:1344-1356.
7. Schotten U., et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011, 91:265-325.
8. Wattigney W.A., et al. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003, 108:711-716.
9. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am. J. Cardiol. 2003, 91:9G-14G.
10. Spodick D.H. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. J. Am. Med. Assoc. 1976, 235:39-416.
11. Frustaci A., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96:1180-1184.
12. Mihm M.J., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180.
13. Bruins P., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997, 96:3542-3548.
14. Dernellis J., Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am. J. Cardiol. 2006, 97:245-248.
15. Toutouzas K., et al. Inflammation in lone atrial fibrillation: new insights by coronary sinus thermography. Int. J. Cardiol. 2009, 134:345-350.
16. Schnabel R.B., et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010, 121:200-207.
17. Smith J.G., et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J. Am. Coll. Cardiol. 2010, 56:1712-1719.
18. Letsas K.P., et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 2009, 11:158-163.
19. Lin Y.J., et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am. J. Cardiol. 2010, 105:495-501.
20. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. 2004, 25:1100-1107.
21. Prasongsukarn K., et al. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial. J. Thorac. Cardiovasc. Surg. 2005, 130:93-98.
22. Leftheriotis D.I., et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol. 2009, 135:361-369.
23. Marcus G.M., et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010, 7:149-154.
24. Henningsen K.M., et al. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand. J. Clin. Lab. Invest. 2009, 69:425-432.
25. Conway D.S., et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J. 2004, 148:462-466.
26. Psychari S.N., et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am. J. Cardiol. 2005, 95:764-767.
27. Carnes C.A., et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ. Res. 2001, 89:E32-E38.
28. Ide T., et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 2000, 86:152-157.
29. Chen C.L., et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J. Mol. Cell. Cardiol. 2008, 45:742-753.
30. Kourliouros A., et al. Current concepts in the pathogenesis of atrial fibrillation. Am. Heart J. 2009, 157:243-252.
31. Dobrev D., Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J. Cardiovasc. Pharmacol. 2008, 52:293-299.
32. Gramley F., et al. Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway. Int. J. Cardiol. 2010, 143:405-413.
33. Saba S., et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1456-H1467.
34. Guerra L., et al. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. Br. J. Pharmacol. 1996, 118:1278-1284.
35. Donoso P., et al. Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front. Biosci. 2011, 16:553-567.
36. 2+ leak in chronic heart failure. Circ. Res. 2008, 103:1466-1472.
37. 2+ depletion in cardiac myocytes. Free Radic. Biol. Med. 2010, 48:1182-1187.
38. Zissimopoulos S., Lai F. Redox regulation of the ryanodine receptor/calcium release channel. Biochem. Soc. Trans. 2006, 34:919-921.
39. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc. Res. 2006, 71:310-321.
40. Chaldoupi S.M., et al. The role of connexin40 in atrial fibrillation. Cardiovasc. Res. 2009, 84:15-23.
41. Wirka R.C., et al. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2011, 4:87-93.
42. Luo M.H., et al. Fibrosis of collagen I and remodeling of connexin 43 in atrial myocardium of patients with atrial fibrillation. Cardiology 2007, 107:248-253.
43. Patel P., et al. Update on the association of inflammation and atrial fibrillation. J. Cardiovasc. Electrophysiol. 2010, 21:1064-1070.
44. Ryu K., et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1231-H1241.
45. Lindsey M.L., et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113:2919-2928.
46. Hagiwara N. Inflammation and atrial fibrillation. Circ. J. 2010, 74:246-247.
47. Verheule S., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ. Res. 2004, 94:1458-1465.
48. Okumura Y., et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J. Cardiovasc. Electrophysiol. 2011, 10.1111/j.1540-8167.2011.02059.x.
49. Yue L., et al. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 2011, 89:744-753.
50. Xu J., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004, 109:363-368.
51. Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011, 79:944-956.
52. Hecker L., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
53. Li Y.Y., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12746-12751.
54. Rudolph V., et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat. Med. 2010, 16:470-474.
55. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16:558-564.
56. Ramos-Mondragón R., et al. Role of TGF-beta on cardiac structural and electrical remodeling. Vasc. Health Risk Manag. 2008, 4:1289-1300.
57. Barcellos-Hoff M.H., Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 1996, 10:1077-1083.
58. Li J., et al. Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 2010, 59:2033-2042.
59. Reil J.C., et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovasc. Res. 2010, 87:485-493.
60. Adam O., et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J. Mol. Cell. Cardiol. 2011, 50:678-685.
61. Fu X., et al. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem. 2003, 278:28403-28409.
62. Wang Y., et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J. Biol. Chem. 2007, 282:31826-31834.
63. Chen M.C., et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am. J. Cardiol. 2008, 102:861-865.
64. Yamashita T., et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ. J. 2010, 74:262-270.
65. Ramlawi B., et al. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann. Thorac. Surg. 2007, 84:1166-1172.
66. Lamm G., et al. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J. Cardiothorac. Vasc. Anesth. 2006, 20:51-56.
67. Finet J.E., et al. Information learned from animal models of atrial fibrillation. Cardiol. Clin. 2009, 27:45-54.
68. Goldstein R.N., et al. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J. Cardiovasc. Electrophysiol. 2008, 19:74-81.
69. Zhang Z., et al. n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int. J. Cardiol. 2010, 10.1016/j.ijcard.2010.08.024.
70. Ishii Y., et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 2005, 111:2881-2888.
71. Goette A., et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008, 117:732-742.
72. McCubrey J.A., et al. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8:1775-1789.
73. Johar S., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006, 20:1546-1548.
74. Balasubramanian S., et al. The interferon-γ-induced GTPase, mGBP-2, inhibits TNF-α induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-κB and Rac. J. Biol. Chem. 2011, 286:20054-20064.
75. Everett T.H., Olgin J.E. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007, 4:S24-S27.
76. Sugden P.H., Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell. Signal. 1997, 9:337-351.
77. Bachschmid M.M., et al. Attenuated cardiovascular hypertrophy and oxidant generation in response to angiotensin II infusion in glutaredoxin-1 knockout mice. Free Radic. Biol. Med. 2010, 49:1221-1229.
78. Li L., et al. Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts. Cardiovasc. Res. 2011, 10.1093/cvr/cvr067.
79. Xu J., et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1328-H1338.
80. El Bekay R., et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 2003, 102:662-671.
81. Zhao W., et al. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol. Cell. Biochem. 2008, 317:43-50.
82. Xiao H.D., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am. J. Pathol. 2004, 165:1019-1032.
83. Lau D., et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:431-436.
84. Klinke A., et al. Myeloperoxidase attracts neutrophils by physical forces. Blood 2011, 117:1350-1358.
85. Aviles R.J., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.